Current Report Filing (8-k)
May 13 2022 - 07:11AM
Edgar (US Regulatory)
0001509745
false
0001509745
2022-05-13
2022-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 13, 2022
Leap Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-37990 |
27-4412575 |
(State or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
47 Thorndike Street, Suite B1-1
Cambridge, MA |
02141 |
(Address of principal executive offices) |
(Zip Code) |
|
|
|
|
Registrant’s telephone
number, including area code: (617) 714-0360
N/A
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
Common Stock, par value $0.001 |
LPTX |
Nasdaq Global Market |
Item 2.02. |
Results of Operations and Financial Condition |
On May 13, 2022, Leap Therapeutics, Inc. (the
“Company”) announced its financial results for the quarter ended March 31, 2022. The full text of the press release
issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained herein and in the accompanying
exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information
in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: May 13, 2022 |
By: |
/s/ Douglas E. Onsi |
| Name: | Douglas E. Onsi |
| Title: | Chief Executive Officer and
President |
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Mar 2023 to Mar 2024